SteinCares and Shilpa Biologicals Form Strategic Partnership to Expand Biosimilar Access Across Latin America
核心洞察
SteinCares (搜索) and Shilpa Biologicals (搜索) have announced a strategic licensing agreement to commercialize a biosimilar (搜索) across Latin America, marking Shilpa's entry into the region.
Under the agreement, SteinCares (搜索) will hold exclusive rights to register and distribute the biosimilar (搜索) while Shilpa Biologicals (搜索) handles development and manufacturing from its Dharwad facility.
The partnership combines Shilpa's biologics development expertise with SteinCares (搜索)' regional commercialization platform to expand patient access to cost-effective treatments.
SteinCares (搜索), a leading specialty healthcare company in Latin America, and Shilpa Biologicals (搜索) Pvt. Ltd., a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited, have announced a strategic licensing agreement to commercialize a biosimilar (搜索) across Latin America. The partnership marks Shilpa Biologicals' entry into the Latin American market and represents the first product from this strategic collaboration.
Partnership Structure and Responsibilities
Under the licensing agreement, SteinCares (搜索) will hold exclusive rights to register, commercialize, and distribute the biosimilar (搜索) across the Latin American region. Meanwhile, Shilpa Biologicals (搜索) will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India.
The collaboration brings together Shilpa Biologicals (搜索)' expertise in biologics development and high-quality commercial manufacturing with SteinCares (搜索)' integrated regional platform, which combines regulatory capabilities, market access, and deep understanding of Latin American healthcare systems.
Leadership Perspectives on Market Expansion
"We are excited to partner with Shilpa Biologicals (搜索) to bring this biosimilar (搜索) to Latin America," said Mitchell Waserstein, CEO of SteinCares (搜索). "This agreement reinforces our leadership in biosimilars and our role as a strategic partner for global biopharmaceutical companies seeking to enter Latin America's complex healthcare markets. By combining Shilpa's proven capabilities in biologics development and manufacturing with our integrated regional platform and deep market expertise, we are creating scalable healthcare opportunities and expanding access to innovative, cost-effective treatments across the region."
Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals (搜索), emphasized the strategic value of the partnership: "SteinCares (搜索) is a trusted partner in Latin America with proven expertise in the registration and commercialization of specialty therapies. Through this licensing agreement, we are entering Latin America and aim to broaden patient access to safe treatments across the region. We believe this collaboration will create meaningful value for patients, healthcare systems, and our organizations as we expand our biosimilars footprint in Latin America."
Strategic Implications and Future Outlook
This partnership builds on SteinCares (搜索)' track record of successfully introducing biosimilars in the region and strengthens its specialty care portfolio. The collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin America.
The agreement also reinforces Shilpa Biologicals (搜索)' commitment to scalable, long-term global licensing partnerships and creates a strong platform for future collaborations across key international markets and their growing biosimilars portfolio. SteinCares (搜索) operates across 30 Latin American countries with over 45 years of experience, offering an integrated one-stop-shop platform pioneering biosimilar (搜索) therapies.
Shilpa Biologicals (搜索) operates as an integrated biopharmaceutical company with a hybrid CDMO model, offering development, manufacturing, and ready-to-license formulations in immunology, oncology, and ophthalmics.